聚乙二醇化重组人粒细胞集落刺激因子在妇科肿瘤中药物利用评价的建立与应用

Establishment and application of drug use evaluation of pegylated recombinant human granulocyte-colony stimulating factor in gynecological oncology

目的了解聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)在本院妇科肿瘤患者中的使用情况,为合理使用PEG-rhG-CSF提供参考。方法参考国内外指南、药品说明书并结合专家咨询,建立妇科肿瘤放/化疗过程中PEG-rhG-CSF的药物利用评价(DUE)标准。用回顾性分析方法,通过医院病例检索系统随机抽取2018年6月至2018年12月入住我院妇科病房的200例患者,共计965例次使用PEG-rhG-CSF的病历。结果 PEG-rhG-CSF的DUE标准包括用药适应证、用药过程和用药结果 3部分,结果发现,本院PEGrhG-CSF应用的不合理现象主要为用法用量不合理(97. 29%)和用药适应证不合理(39. 90%)。结论 PEG-rhG-CSF在妇科肿瘤中DUE标准的建立,可为临床医师和临床药师合理应用该药提供参考。

Objective To understand the use of PEG - rhG - CSF ( pegylated recombinant human granulocyte - colony stimulating factor) in patients with gynecologic tumors in our hospital,and to provide reference for the rational use of PEG - rhG - CSF. Methods Based on the domestic and foreign guidelines,package inserts and expert consultation,a drug use evaluation ( DUE) criteria for the use of PEG - rhG - CSF in gynecology during the chemoradiotherapy was established. A retrospective analysis method was used to randomly select 200 patients who were treated with PEG - rhG - CSF in the gynecological ward of our hospital from June to December 2018 and 965 cases of medical records were collected. Results The DUE criterion for PEG - rhG - CSF consisted of medication indication,medication course and medication results. The results showed that the irrational use of PEG - rhG - CSF mainly manifested in unreasonable usage or dosage ( 97. 29%),and indicative use of drugs ( 39. 90%). Conclusion The establishment of DUE criteria for PEG - rhG - CSF can provide a reference for physicians and clinical pharmacists to rationally apply for this drug.